Dermata Therapeutics Warrant Stock Beneish M Score

DRMAW Stock  USD 0.01  0.00  0.00%   
This module uses fundamental data of Dermata Therapeutics to approximate the value of its Beneish M Score. Dermata Therapeutics M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
  
At this time, Dermata Therapeutics' Debt To Assets are fairly stable compared to the past year. Debt Ratio is likely to climb to 5.53 in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 2.7 M in 2024. At this time, Dermata Therapeutics' Shareholders Equity Per Share is fairly stable compared to the past year. Graham Net Net is likely to climb to 31.50 in 2024, despite the fact that Operating Cash Flow Per Share is likely to grow to (31.38).
At this time, it appears that Dermata Therapeutics is an unlikely manipulator. The earnings manipulation may begin if Dermata Therapeutics' top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Dermata Therapeutics executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Dermata Therapeutics' earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-6.49
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

N/A

Focus
Asset Quality

N/A

Focus
Expense Coverage

N/A

Focus
Gross Margin Strengs

N/A

Focus
Accruals Factor

N/A

Focus
Depreciation Resistance

N/A

Focus
Net Sales Growth

N/A

Focus
Financial Leverage Condition

1.18

Focus

Dermata Therapeutics Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Dermata Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables8.4 K8.4 K
Slightly Up
Slightly volatile
Total Assets6.4 MM
Significantly Down
Slightly volatile
Total Current Assets6.4 MM
Significantly Down
Slightly volatile
Depreciation And Amortization8.4 MM
Sufficiently Up
Slightly volatile
Selling General Administrative3.5 MM
Fairly Down
Slightly volatile
Total Current Liabilities1.5 M1.6 M
Notably Down
Very volatile
Non Current Liabilities Total795.5 M757.6 M
Sufficiently Up
Slightly volatile
Short Term Debt2.4 M4.1 M
Way Down
Slightly volatile
Long Term Debt442.6 K497.9 K
Fairly Down
Slightly volatile

Dermata Therapeutics Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Dermata Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Dermata Therapeutics in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Dermata Therapeutics' degree of accounting gimmicks and manipulations.

About Dermata Therapeutics Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

8.44 Million

At this time, Dermata Therapeutics' Depreciation And Amortization is fairly stable compared to the past year.

About Dermata Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Dermata Stock Analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.